1. Outcome of allogeneic haematopoietic cell transplantation in eosinophilic disorders: A retrospective study by the chronic malignancies working party of the EBMT.
- Author
-
McLornan, Donal P., Gras, Luuk, Martin, Ivonne, Sirait, Tiarlan, Schroeder, Thomas, Blau, Igor Wolfgang, Kuball, Jürgen, Byrne, Jenny, Collin, Matthew, Stadler, Michael, Desmier, Déborah, Salmenniemi, Urpu, Jindra, Pavel, Mikhailova, Natalia, Lenhoff, Stig, Rifón, Jose, Robin, Marie, Rovira, Montserrat, Veelken, Hendrik, and Sadowska‐Klasa, Alicja
- Subjects
HYPEREOSINOPHILIC syndrome ,CELL transplantation ,GRAFT versus host disease - Abstract
Patients were transplanted with a median time to allo-HCT of 15.1 months (IQR, 9.8-27.9) for CEL, NOS patients, and 22.2 months (IQR, 11.5-55.8; I p i = 0.01) for HES. Helbig et al. reported on 10 patients with CEL, NOS with a median age of 62 (23-73 years), frequently with an aggressive clinical course, five of whom developed acute transformation within two years from the time of diagnosis.6 Here, only one patient in the chronic phase successfully underwent allo-SCT. Keywords: allogeneic stem cell transplant; chronic eosinophilic leukaemia; conditioning; hypereosinophilic syndrome; non-relapse mortality EN allogeneic stem cell transplant chronic eosinophilic leukaemia conditioning hypereosinophilic syndrome non-relapse mortality 209 213 5 06/27/22 20220701 NES 220701 Hypereosinophilic syndrome (HES) and chronic eosinophilic leukaemia (CEL), not otherwise specified (NOS) are rare haematological disorders.1 Allogeneic haematopoietic cell transplantation (allo-HCT) has been reported in single case reports or small case series only for both refractory HES or CEL, NOS and outcomes remain ill-defined.1-3 HES normally demonstrates a male predominance, likely underrecognized, with a variable clinical course. [Extracted from the article]
- Published
- 2022
- Full Text
- View/download PDF